News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC
Guilherme Nader Marta/X
Feb 2, 2025, 01:46

Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC

Guilherme Nader Marta, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Michail Ignatiadis et al. published in JAMA:

“Phase 3 ALEXANDRA/IMpassion030 trial (n=2199) published in JAMA found no benefit of adjuvant atezolizumab and chemo vs chemo alone for high-risk early-stage TNBC (IDFS HR 1.11, 95% CI 0.87-1.42).

Higher grade 3-4 toxicity (54% vs 44%).”

“Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial”

Authors: Michail Ignatiadis et al.

Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC

More posts featuring Guilherme Nader Marta.

atezolizumab cancer Guilherme Nader Marta Michail ignatiadis OncoDaily Oncology TNBC
Special Coverage
Insight
Feb 2, 2025, 01:46
Guilherme Nader Marta: Phase 3 ALEXANDRA/IMpassion030 trial found no benefit of adjuvant atezolizumab and chemo for TNBC
Insight
Feb 2, 2025, 01:42
María Natalia Gandur Quiroga: Men’s Attitudes Towards Participation in Organised Prostate Cancer Testing
Career
Feb 2, 2025, 01:38
Jonathan Rosenberg: Celebrating the illustrious career of Dean Bajorin
Blog
Feb 2, 2025, 01:37
Aref Al-Kali: New concept and potential biological subgroup for relapsed or refractory AML
Insight
Feb 2, 2025, 01:35
Anna Berkenblit: Key pancreatic cancer research updates from ASCO GI25
Insight
Feb 2, 2025, 01:32
Chiara Mercinelli: Honored to receive the Best Publication in Urological Oncology award
Blog
Feb 2, 2025, 00:59
The benefits and challenges of cancer registries in global cancer care - The Lancet
Blog
Feb 2, 2025, 00:57
Patient-Reported Incidence of Fatigue During Palbociclib and Endocrine Therapy in Advanced HR+ HER2- Breast Cancer
Insight
Feb 2, 2025, 00:54
Chad Tang: Optimizing breath-hold continuous motion gating for kidney cancer
Blog
Feb 2, 2025, 00:52
Stephen V Liu: Will G12D inhibitors emerge or pan KRAS or pan RAS?
Blog
Feb 1, 2025, 19:23
Mohit Manrao: Incredible work around the globe in oncology
Blog
Feb 1, 2025, 19:21
E. Anders Kolb rang the Nasdaq opening bell on behalf of all blood cancer patients and their families